<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:34:12Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2685087" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2685087</identifier><datestamp>2009-05-21</datestamp><setSpec>nar</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <?epub April-1-2009?>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
      <journal-id journal-id-type="publisher-id">nar</journal-id>
      <journal-id journal-id-type="hwp">nar</journal-id>
      <journal-title-group>
        <journal-title>Nucleic Acids Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0305-1048</issn>
      <issn pub-type="epub">1362-4962</issn>
      <publisher>
        <publisher-name>Oxford University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2685087</article-id>
      <article-id pub-id-type="pmcid">PMC2685087</article-id>
      <article-id pub-id-type="pmc-uid">2685087</article-id>
      <article-id pub-id-type="pmid">19339517</article-id>
      <article-id pub-id-type="pmid">19339517</article-id>
      <article-id pub-id-type="doi">10.1093/nar/gkp136</article-id>
      <article-id pub-id-type="publisher-id">gkp136</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Molecular Biology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>CK1Î´ modulates the transcriptional activity of ERÎ± via AIB1 in an estrogen-dependent manner and regulates ERÎ±âAIB1 interactions</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Giamas</surname>
            <given-names>Georgios</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Castellano</surname>
            <given-names>Leandro</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Feng</surname>
            <given-names>Qin</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Knippschild</surname>
            <given-names>Uwe</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jacob</surname>
            <given-names>Jimmy</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thomas</surname>
            <given-names>Ross S.</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coombes</surname>
            <given-names>R. Charles</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>Carolyn L.</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jiao</surname>
            <given-names>Long R.</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stebbing</surname>
            <given-names>Justin</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="COR1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="AFF1"><sup>1</sup>Department of Medical Oncology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 ONN, UK, <sup>2</sup>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA and <sup>3</sup>Department of General-, Visceral- and Transplantation Surgery, University of Ulm, D 89075 Ulm, Germany</aff>
      <author-notes>
        <corresp id="COR1">*To whom correspondence should be addressed. Tel: <phone>+44 208 7468295</phone>; Fax: <fax>+44 208 8461433</fax>; Email: <email>g.giamas@imperial.ac.uk</email> or <email>j.stebbing@imperial.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>1</day>
        <month>4</month>
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>4</month>
        <year>2009</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
      <volume>37</volume>
      <issue>9</issue>
      <fpage>3110</fpage>
      <lpage>3123</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>1</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>2</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>2</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2009 The Author(s)</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">
          <license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Oncogenesis in breast cancer often requires the overexpression of the nuclear receptor coactivator AIB1/SRC-3 acting in conjunction with estrogen receptor-Î± (ERÎ±). Phosphorylation of both ERÎ± and AIB1 has been shown to have profound effects on their functions. In addition, proteasome-mediated degradation plays a major role by regulating their stability and activity. CK1Î´, a member of the ubiquitous casein kinase-1 family, is implicated in the progression of breast cancer. In this study, we show that both ERÎ± and AIB1 are substrates for CK1Î´ <italic>in vitro</italic>, and identify a novel AIB1 phosphorylation site (S601) targeted by CK1Î´, significant for the co-activator function of AIB1. CK1Î´ is able to interact with ERÎ± and AIB1 <italic>in vivo</italic>, while overexpression of CK1Î´ in breast cancer cells results in an increased association of ERÎ± with AIB1 as confirmed by co-immunoprecipitation assays from cell lysates. Using an siRNA-based approach, luciferase reporter assays and qRT-PCR, we observe that silencing of CK1Î´ leads to reduced ERÎ± transcriptional activity, despite increased ERÎ± levels, similarly to proteasome inhibition. We provide evidence that AIB1 protein levels are reduced by CK1Î´ silencing, in an estradiol-dependent manner; such destabilization can be inhibited by pre-treatment with the proteasome inhibitor MG132. We propose that differing activities adopted by ERÎ± and AIB1 as a consequence of their interactions with and phosphorylation by CK1Î´, particularly AIB1 stabilization, influence the transcriptional activity of ERÎ±, and therefore have a role in breast cancer development.</p>
      </abstract>
    </article-meta>
  </front>
  <body><sec><title>INTRODUCTION</title><p>Estrogen receptor alpha (ERÎ±), a member of the nuclear receptor (NR) superfamily of transcription factors, has been one of the most successful therapeutic targets for breast cancer (<xref ref-type="bibr" rid="B1">1</xref>). It contains 595 amino acids with a central DNA-binding domain (DBD) and transcriptional activation occurs through at least two distinct transactivation domains located in the amino-terminal A/B region (AF-1) and the carboxy terminal E region of the receptor (AF-2). The AF-1 domain is hormone-independent, whereas the AF-2 domain is estrogen-dependent; both AF domains are required for maximal ERÎ± transcriptional activity (<xref ref-type="bibr" rid="B2">2</xref>). In addition to being activated upon binding estrogen, we and others have shown that ERÎ± can be activated by phosphorylation (<xref ref-type="bibr" rid="B3">3</xref>). Activation of ERÎ± is also coupled with its degradation by the ubiquitin-proteasome pathway (<xref ref-type="bibr" rid="B4 B5 B6">4â6</xref>). Upon ligand binding, ERÎ± becomes ubiquitinated and is targeted by the 26S proteasome for degradation (<xref ref-type="bibr" rid="B7">7</xref>). However, various direct or indirect mechanisms have been described that can protect ERÎ± from proteasomal degradation and thereby modulate its transcriptional activity including the involvement of the Amplified in breast cancer-1 (AIB1) protein (<xref ref-type="bibr" rid="B8 B9 B10">8â10</xref>).</p><p>AIB1 (SRC-3/ACTR/pCIP/RAC3), a p160 co-activating oncogene overexpressed in different types of cancer, especially breast tumors (<xref ref-type="bibr" rid="B11">11</xref>), associates with and regulates ERÎ± transcriptional activity; AIB1 recruits co-factors that possess histone acetyl-transferase activity and thus increases ERÎ± transcriptional activity through chromatin remodeling (<xref ref-type="bibr" rid="B12 B13 B14">12â14</xref>). Interestingly, it has been reported that AIB1 also regulates ERÎ± turnover through recruitment of components of the ubiquitin-proteasome pathway. Suppression of AIB1 leads to ERÎ± stabilization in the presence of estradiol (E2) and subsequent reduction of ERÎ± transcriptional activity (<xref ref-type="bibr" rid="B15">15</xref>). The activity of AIB1 is modulated post-transcriptionally by phosphorylation which results in increased AIB1 degradation (<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>). Recently, atypical protein kinase C (aPKC) has been shown to stabilize AIB1 protein levels in cancer cells (<xref ref-type="bibr" rid="B10">10</xref>), supporting the existence of an equilibrium of different kinases implicated in the promotion and prevention of AIB1 degradation, so called dual kinase regulation.</p><p>Casein kinase 1 (CK1), a highly conserved Ser/Thr protein kinase family, is ubiquitously expressed in all eukaryotic organisms (<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>) and alterations in the expression and/or activity of CK1 have been observed in breast carcinomas (<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>). Among CK1 isoforms, CK1Î´ is able to phosphorylate a diversity of substrates, modulating their activity and subcellular localization (<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B21">21</xref>). As changes in the activity of CK1Î´, or mutations of CK1Î´-specific phosphorylation sites within it's substrates, contribute to dysregulation of various signaling pathways (<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B22 B23 B24 B25">22â25</xref>), we wished to establish the role of CK1Î´ in the regulation of ERÎ± activity.</p><p>Here, we observe that CK1Î´ can interact with and phosphorylate both AIB1 and ERÎ± <italic>in vitro</italic>. Furthermore, overexpression of CK1Î´ protein levels in MCF7 cells enhanced the interactions between ERÎ± and AIB1. CK1Î´ silencing results in decreased ERÎ± transcriptional activity even though paradoxically ERÎ± levels appear increased. Moreover, these results demonstrate that the effects of CK1Î´ silencing on AIB1 can be rescued by proteasomal inhibition, suggesting that phosphorylation of AIB1 by CK1Î´ protects it from degradation. Finally we identify S601 in AIB1, a hitherto unidentified site, as the main phosphorylation aa targeted by CK1Î´, which is required for the activity of AIB1. These data herein, and recent evidence regarding dual kinase regulation (<xref ref-type="bibr" rid="B10">10</xref>), suggest a general mechanism by which the characteristics of the AIB1âERÎ± partnership can be modulated by CK1Î´-mediated phosphorylation.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Chemicals and reagents</title><p>E2 was obtained from Sigma (Gillingham, UK) and dissolved in ethanol; Charcoal-dextran stripped serum (DSS) was obtained from Gemini (Bolnet, UK). The cell-permeable proteasome inhibitor MG132 and the kinase inhibitor IC261 were obtained from Merck (Nottingham, UK). Rabbit polyclonal CK1Î´ antibody was from Santa Cruz (Heidelberg, Germany); mouse monoclonal ERÎ±, rabbit monoclonal anti-phosphoERÎ±âS118 and anti-Î²-actin mouse monoclonal antibodies were purchased from Abcam (Cambridge, UK) and Millipore (Southampton, UK) respectively. HRP (horseradish peroxidase)-conjugated goat anti-rabbit IgG and goat anti-mouse IgG antibodies were from GE Healthcare (Slough, UK).</p></sec><sec><title>Plasmids</title><p>The expression plasmid for yellow fluorescent protein (EYFP)âCK1Î´ was constructed as follows. PCR amplification was carried out using mouse testis cDNA as a template and the CK1Î´ primers: 5â²-<underline>GGATCC</underline>ATGGAGCTGAGGGTCGGGACA-3â², 3â²-<underline>GGATCC</underline>TCAGTAGGTGGTACGTCGTGG-5â², which contain a BamH1 restriction site (underlined). The PCR product was then cloned into the multiple cloning site of pcDNA3.1/V5-His-TOPO vector (Invitrogen, Paisley, UK) and then subcloned into the BamH1 site of pEYFP vector (BD Biosciences Clontech, Heidelberg, Germany). The expression plasmid for human Flag-tagged AIB1 (pCMV-Flag-AIB1) was generated as described previously (<xref ref-type="bibr" rid="B26">26</xref>). The expression plasmids: (i) pSG5-ERÎ± (<xref ref-type="bibr" rid="B27">27</xref>) and (ii) pGEX4TâAIB1 (encompassing amino acids 582â800) (<xref ref-type="bibr" rid="B26">26</xref>) were kind gifts from Professors Simak Ali and Bert W. OâMalley respectively.</p></sec><sec><title>Site-directed mutagenesis</title><p>The expression plasmid pCMV-Flag-AIB1 baring a mutation at aa S601A was generated using the QuikChange site-directed mutagenesis kit according to manufacturer<bold>'</bold>s instructions (Stratagene). The plasmid pCMV-Flag-AIB1 served as a template and the complementary primers used were: 5â²-GACAAAGAAAGTAAGGAGGCCAGTGTTGAGGGGGCAGAG-3â² (sense) and 5â²-CTCTGCCCCCTCAACACTGGCCTCCTTACTTTCTTTGTC-3â² (antisense). The plasmids pGEX4TâAIB1 aa 582â800 containing mutations at aas: S601A, S664A, T714A, S715A and S794 of AIB1, were constructed using the plasmid pGEX4TâAIB1 582â800 as a template and the following complimentary primers: (i) S601A: 5â²-GACAAAGAAAGTAAGGAGGCCAGTGTTGAGGGGGCAGAG-3â² (sense) and 5â²-CTCTGCCCCCTCAACACTGGCCTCCTTACTTTCTTTGTC-3â² (antisense), (ii) S664A: 5â²-GTCTCCTCCTCTACAGCTGG AGGAGTATCCTC-3â² (sense) and 5â²-GAGGATACTCCTCCAGCTGTAGAGGAGGAGAC-3â² (antisense), (iii) T714A: 5â²-GACA CCAGCAGTATAGCTTCTTGTGGGACGG-3â² (sense) and 5â²-CCGTCCCCACAAGAAGCTATACTGCTGGTGTC-3â² (antisense), (iv) S715A: 5â²-CCAGCAGTATAACTGCTTGTGGGGACGGAAATG-3â² (sense) and 5â²-CATTTCCGTCCCCACAAGCAGTTATACTGCTGG-3â² (antisense), (v) S794A: 5â²-GACAAGTGAAGAGGGAGCTGGAGACTTGGATAATC-3â² (sense) and 5â²- GATTATCCAAGTCTCCAGCTCCCTCTTCACTTGTC-3â² (antisense).</p></sec><sec><title>Cell culture and transfections</title><p>MCF7, T47D, MELN (<xref ref-type="bibr" rid="B28">28</xref>) and COS-1 cells were maintained in DMEM supplemented with 10% DSS, 1% penicillin/streptomycin and 2% glutamine. HeLa cell line expressing wild-type ERÎ± has been described elsewhere (<xref ref-type="bibr" rid="B29">29</xref>) (a kind gift from Dr Shapiro). All cells were incubated at 37Â°C in a humidified 5% CO<sub>2</sub> atmosphere. MCF7 and MELN cells were transfected with 5ânM siRNA using Hiperfect according to the manufacturer's instructions (Qiagen, Crawley, UK). Transient transfections of COS-1 and MCF7 were performed 24âh after seeding cells using FuGENE 6 according to the manufacturer's instructions (Roche, Sussex, UK). Cells were maintained in phenol red-free media with 5% charcoal-stripped serum 48âh before experimentation. The CK1Î´ isoform was silenced using two independent siRNAs, targeting the following sequences: 5â²-ccggtct aggatcgaaatgtt-3â² and 5â²-ctccctgacgattccactgta-3â². At 48âh (or 72âh) post-transfection, cells were treated with either vehicle (ethanol) or E2, and harvested later (as indicated) for RNA or protein analyses.</p></sec><sec><title>RNA isolation and quantitative RT-PCR</title><p>Isolation of total RNA was performed using the RNeasy kit (Qiagen). RNA (1âÎ¼g) was reverse transcribed using oligo (deoxythymidine) primers (Qiagen) and SuperScript II reverse transcriptase (Invitrogen). Quantitative RT-PCRs using the TaqMan mastermix (Applied Biosystems) were performed on a 7900HT Thermocycler (Applied Biosystems, Warrington, UK) using primers for pS2, PR and GAPDH cDNAs, purchased from Applied Biosystems.</p></sec><sec><title>Firefly luciferase assay</title><p>MELN cells (0.5âÃâ10<sup>6</sup>) were plated in 24-well plates in medium containing DMEM/10% DSS for 24âh, transfected with CK1Î´ siRNA for 48âh and treated with E2 (10ânM) or vehicle (ethanol) for 24âh. The cells were washed twice with PBS and lysed in 50âÎ¼l/well luciferase cell culture lysis reagent (Promega, Southampton, UK). Luciferase assays were performed using the firefly luciferase assay system from Promega, according to the manufacturer's instructions, and measured with a Top Count NXT luminometer (Packard Biosciences, Beaconsfield, UK). All experiments were performed independently at least three times, and results presented as the mean with standard error of the mean error bars. Data are normalized to the untreated sample, which was given a reference value of one.</p></sec><sec><title>Western blotting and SDSâPAGE</title><p>Whole cell lysates were prepared in NP40 lysis buffer (50âmM TrisâHCl, pH 8.0, 150âmM NaCl, 10% (v/v) glycerol, 1% NP40, 5âmM dithiothreitol (DTT), 1âmM EDTA, 1âmM EGTA, 50âÂµM leupeptin and 30âÂµg/ml aprotinin). For western blotting, extracts were clarified by centrifugation at 15â000<italic>g</italic> for 20âmin at 4Â°C and the protein concentration of the lysates was determined using the bicinchoninic acid (BCA) protein assay (Pierce, Cramlington, UK). Lysates were then boiled in 5Ã sodium dodecyl sulfate (SDS) sample buffer (5âmin, 95Â°C), subjected to 12.5% SDSâPAGE and blotted on a Hybond C super nitrocellulose membrane (GE Healthcare). Following this, the membranes were blocked in TBS containing 0.1% (v/v) Tween20 and 5% (w/v) non-fat milk for 1âh, before probed overnight (O/N) with different antibodies in the same buffer, and washed extensively in TBS/Tween. Immunocomplexes were detected by incubation for 45âmin with HRP-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (1:1000 dilution), followed by enhanced chemiluminescence detection (ECL) (GE Healthcare). The intensity of bands were quantified using Image J software (NIH, Bethesda, MD).</p></sec><sec><title>Immunoprecipitation</title><p>Cells lysates were cleared by centrifugation (15â000ârpm, 10âmin, 4Â°C). Lysates containing equal amounts of proteins were precleared with IgG bound to protein A or G-agarose beads (Sigma) for 12âh at 4Â°C and immunoprecipitated with the specific primary antibody and protein A or protein G-agarose overnight with gentle agitation. The precipitates were then subjected to SDSâPAGE and immunoblotting using phosphospecific primary antibodies and horseradish peroxidase-labeled secondary antibodies.</p></sec><sec><title><italic>In vitro</italic> kinase assays</title><p><italic>In vitro</italic> kinase assays were carried out as described previously (<xref ref-type="bibr" rid="B23">23</xref>). ERÎ±-substrates that were used were: (i) full-length recombinant human ERÎ±, (ii) GST-recombinant human ERÎ± fragment encompassing the AF1 transactivation domain and the DNA-binding domain (aa 1â280) and (iii) GST-recombinant human ERÎ± fragment encompassing the ligand-binding domain (LBD) (aa 283â595). AIB1-substrates were: (i) full-length purified AIB1 and (ii) different GST-recombinant human AIB1 fragments encompassing the RID region, responsible for ligand-dependent interaction with NRs (aa 582â800) (wt and those containing mutations at the following AIB1 aas: S601A, S664A, T714A, S715A and S794A). As a source of enzyme activity we used GST-tagged recombinant human CK1Î´ protein (Invitrogen). Phosphorylated proteins were resolved by SDSâPAGE and the protein bands were visualized by autoradiography. Where indicated, the phosphorylated protein bands were excised and quantified by Cherenkov counting using LS-6500 scintillation counter (Beckman Coulter, San Francisco, CA, USA).</p></sec><sec><title>Immunofluorescence</title><p>MCF-7 cells were grown on poly-<sc>d</sc>-lysine-coated glass coverslips for 24âh in DMEM/10% DSS. Next, cells were transfected with CK1Î´ siRNA or vehicle (ethanol) for 48âh and treated with E2 (10ânM) for 24âh. Cells were then washed twice in PBS and fixed in methanol for 15âmin at 20Â°C. Fixed cells were washed with PBS and blocked with 0.2% gelatin in PBS for 1âh, before incubating them with AIB1 anti-rabbit antibody (1:300 in PBS) for 45âmin at room temperature. After washing with PBS, coverslips were incubated for 45âmin at RT with Alexa 488 secondary antibody (Invitrogen). DNA was visualized by DAPI staining. Cells were examined on an Axiovert-200 laser scanning inverted microscope (Zeiss, Welwyn Garden City, UK) equipped with a confocal imaging system.</p></sec><sec><title>Statistical analysis</title><p>Exploratory data analysis demonstrated that the distributions were often skewed with outliers. ShapiroâWilks test was used to test for normality (data were not normally distributed) and between group comparisons were made using the non parametric MannâWhitney U-test.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>CK1Î´ silencing modulates ERÎ± transcriptional activity and decreases E2-induced expression of ERÎ± regulated genes</title><p>To investigate the involvement of CK1Î´ in E2-dependent transcriptional activation of ERÎ±, MELN cells (MCF7 cells, stably transfected with a luciferase reporter gene under the control of an estrogen response element using the Î²-globin promoter) were transfected with negative control siRNA (CT siRNA) or CK1Î´ siRNA (5ânM), treated with 10ânM E2 for 24âh, and luciferase activities measured. Treatment with E2 alone resulted in a 20-fold induction of luciferase activity. There were no effects of CT siRNA on the activity of ERÎ± in this assay. However, in the presence of CK1Î´ siRNA the E2-dependent luciferase activity was decreased 35%, implying an association of CK1Î´ in E2-induced ERÎ± activation (<xref ref-type="fig" rid="F1">Figure 1</xref>A). Quantitative real-time PCR (qRT-PCR) confirmed â¼80% reduced CK1Î´ mRNA levels after siRNA treatment (<xref ref-type="fig" rid="F1">Figure 1</xref>B).
<fig id="F1" position="float"><label>Figure 1.</label><caption><p>CK1Î´ silencing decreases the transcriptional activity of ERÎ± and downregulates E2-induced expression of ERÎ± target genes. (<bold>A</bold>) MELN cells (5âÃâ10<sup>4</sup>) were plated in 24-well plates in phenol red-free DMEM containing 10% stripped DSS. Cells were transfected with 5ânM scrambled siRNA (CT siRNA) or with 5ânM CK1Î´ siRNA for 48âh and incubated with or without E2 (10ânM) for 24âh. ERE-dependent gene expression was quantified by measuring luciferase activity, given as fold of control. Error bars represent SD of two experiments. (<bold>B</bold>) Quantitative real-time RTâPCR validation of down-regulation of CK1Î´ mRNA levels after treatment with 5ânM siRNA. MCF7 cells (2âÃâ10<sup>5</sup>) were plated in 6-well plates in phenol red-free DMEM containing 10% DSS. Cells were transfected either with 5ânM CT siRNA or with 5ânM siRNA targeting CK1Î´ and treated or not (vehicle) with E2 (10ânM) for 24âh. Cells were harvested and total RNA was extracted and used to synthesize cDNA by reverse transcription, as described in âMaterials and Methodsâ section. Gene expression of (<bold>C</bold>) pS2 and (<bold>D</bold>) PR was measured by quantitative real-time RTâPCR. MCF-7 cells (2âÃâ10<sup>5</sup>) were plated in 6-well plates in phenol red-free DMEM containing 10% DSS. Following, cells were incubated for 24âh with 1Î¼M of the CK1Î´/Ïµ-specific inhibitor IC261 and treated or not (vehicle) with E2 (10ânM) for 24âh. Cells were harvested and total RNA was extracted and used to synthesize cDNA by reverse transcription, as described in âMaterials and Methodsâ section. Gene expression of (<bold>E</bold>) pS2 and, (<bold>F</bold>) PR was measured by quantitative real-time RTâPCR. Transfection of MCF7 cells with a (EYFP)-CK1Î´ plasmid resulted in an increase of (<bold>G</bold>) pS2 expression. GAPDH was used for normalisation. Error bars represent SD of two separate experiments, each in triplicate; changes observed throughout these experiments were statistically significant (<italic>P</italic>â&lt;â0.05).</p></caption><graphic xlink:href="gkp136f1"/></fig></p><p>We next examined the effects of CK1Î´ silencing on ER-regulated gene expression by performing qRT-PCR for two well-known estrogen-induced genes (pS2 and PR). Treatment of MCF7 cells with CK1Î´ siRNA for 48âh reduced expression of both pS2 and PR, by 55% and 43%, respectively (<xref ref-type="fig" rid="F1">Figure 1</xref>C and D). These results, in conjunction with the luciferase assay performed in MELN cells, confirmed either a direct or indirect involvement of CK1Î´ in the regulation of ERÎ± target gene expression. Use of 1Î¼M IC261 (<xref ref-type="bibr" rid="B30">30</xref>), a small molecule inhibitor preferentially inhibiting the CK1Î´ and Îµ isoforms, resulted in a higher reduction of pS2 and PR expression (69% and 66%, respectively) (<xref ref-type="fig" rid="F1">Figure 1</xref>E and F). This difference can be explained by the fact that the use of siRNA knocked down â¼80% of CK1Î´; therefore the lesser effect on gene expression after siRNA treatment, compared to IC261 treatment, is due to the residual CK1Î´. To establish whether downregulation of ERÎ±-targeted genes expression is partly due to CK1Î´ catalytic suppression, we transfected MCF7 cells for 24âh with an expression plasmid encoding EYFP-CK1Î´. Overexpression of CK1Î´ (confirmed by western blotting) resulted in a â¼2-fold increase in E2-induced expression of pS2 (<xref ref-type="fig" rid="F1">Figure 1</xref>G), demonstrating that the presence of CK1Î´ regulates ERÎ± target gene expression.</p></sec><sec><title>ERÎ±âS118 is not targeted for phosphorylation by CK1Î´</title><p>Since we have previously shown that phosphorylation at S118 of ERÎ± is implicated in regulation of transcriptional activation (<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>), we analyzed the effects of CK1Î´ silencing on phosphorylation of ERÎ±. MCF7 cells, untransfected or transfected with either CT siRNA or CK1Î´ siRNA, were stimulated for 30âmin with 100ânM E2 and then probed for ERÎ± phospho-S118. Short-term E2 treatment induced ERÎ± phosphorylation at S118 in both untransfected and control siRNA-transfected cells (<xref ref-type="fig" rid="F2">Figure 2</xref>A). This phosphorylation was not suppressed by CK1Î´ siRNA, but was instead increased (<xref ref-type="fig" rid="F2">Figure 2</xref>A and B). Furthermore, the total ERÎ± protein content was also increased in the CK1Î´ siRNA-treated cells. Quantification and comparison of the phospho-S118:ERÎ± ratio in treated and untreated MCF7 cells implicated upregulation of ERÎ± protein levels as cause of the increase in observed ERÎ± phospho-S118 phosphorylation levels (<xref ref-type="fig" rid="F2">Figure 2</xref>B).
<fig id="F2" position="float"><label>Figure 2.</label><caption><p>CK1Î´ does not phosphorylate ERÎ± at S118. (<bold>A</bold>) MCF7 cells (2âÃâ10<sup>5</sup>) were plated in 6-well plates in phenol red-free DMEM containing 10% DSS. Cells were untransfected or transfected with 5ânM CT siRNA or with 5ânM CK1Î´ siRNA for 72âh and treated or not with E2 (100ânM) for 45âmin. Cells were harvested, lysed and equal protein amounts were subjected to Western blotting analysis using the indicated antibodies. Î²-actin was used as a control for sample loading. Immunoblot showing silencing of CK1Î´. (<bold>B</bold>) Quantitative analysis of ERÎ± pS118, ERÎ± protein levels and the pS118:ERÎ± ratio is given as fold of control. (<bold>C</bold>) Western blotting of the levels of ERÎ± expressed in the stably transfected Hela-ERÎ± cell line. (<bold>D</bold>) Hela-ERÎ± cells untransfected or transfected with 5ânM CT siRNA or with 5ânM CK1Î´ siRNA for 72âh were treated or not with E2 (100ânM) for 45âmin. Cell extracts were immunoblotted. (<bold>E</bold>) Quantitative analysis of ERÎ± phospho-S118, is given as fold of control. All data are representative of results from two independent experiments. Error bars represent SD of two separate experiments in triplicate.</p></caption><graphic xlink:href="gkp136f2"/></fig></p><p>In order to further validate that ERÎ±âS118 is not phosphorylated by CK1Î´ <italic>in vivo</italic>, we used a stably transfected HeLa cell line expressing wild-type ERÎ± (<xref ref-type="fig" rid="F2">Figure 2</xref>C). Compared with E2 treatment, CK1Î´ siRNA failed to reduce the phosphorylation of S118 in Hela-ERÎ± cells (<xref ref-type="fig" rid="F2">Figure 2</xref>D and E). These results indicate that the involvement of CK1Î´ in the regulation of ERÎ± transcriptional activation is not mediated via phosphorylation at S118, but could result from phosphorylation either at: (i) other ERÎ± site(s) or (ii) proteins that interact and modulate ERÎ± activity.</p></sec><sec><title>CK1Î´ silencing stabilizes ERÎ± protein levels in breast cancer cell lines</title><p>Next, we investigated protein levels of ERÎ± following inhibition of the proteasome in the presence of E2 (100ânM). Addition of MG132 (5âÎ¼M), a cell permeable proteasome inhibitor, prevented ERÎ± degradation in E2-treated MCF7 (<xref ref-type="fig" rid="F3">Figure 3</xref>A and B) and T47D breast cancer cells (<xref ref-type="fig" rid="F3">Figure 3</xref>C and D) Moreover, in the presence of E2, both CK1Î´ silencing and MG132 treatment elevated ERÎ± levels, while co-treatment resulted in further increases. Similar results were obtained in MCF7 cells, using another independent CK1Î´ siRNA, ensuring that the data do not reflect off-target effects (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp136/DC1">Supplementary Figure 1A and B</ext-link>). Finally, in order to investigate whether the observed CK1Î´ silencing-related increase of ERÎ± protein levels might be induced by an increase of ERÎ± gene transcription, we performed qRT-PCR and examined the ERÎ± mRNA expression levels upon CK1Î´-siRNA treatment. Our results did not reveal any significant alteration of ERÎ± mRNA following CK1Î´ RNA interference (data not shown). Taken together, these data suggest that CK1Î´ is implicated in the stabilization of ERÎ± in E2-stimulated cells, potentially through direct or indirect phosphorylation events.
<fig id="F3" position="float"><label>Figure 3.</label><caption><p>CK1Î´ silencing stabilizes ERÎ± protein levels. (<bold>A</bold>) MCF7 or, (<bold>C</bold>) T47D cells were untransfected or transfected with 5ânM CK1Î´ siRNA for 72âh. MG132 (5âÎ¼M) was added for 6âh and following cells were treated with E2 (100ânM) for 45âmin. Cell extracts were immunoblotted. Immunoblot showing silencing of CK1Î´. Quantitative analysis of ERÎ± protein levels with or without MG132 pretreatment in the presence of E2 in (<bold>B</bold>) MCF7 or, (<bold>D</bold>) T47D cells. All data are representative of results from two independent experiments. Error bars represent SD of two separate experiments in triplicate.</p></caption><graphic xlink:href="gkp136f3"/></fig></p></sec><sec><title>CK1Î´ silencing decreases AIB1 protein levels in the presence of E2</title><p>We have demonstrated that inhibition of CK1Î´ leads to a decrease in ERÎ± transcriptional activity and a reduction of E2-responsive gene expression, whilst stabilizing ERÎ± protein levels. Related âcontradictoryâ or apparently âparadoxicalâ observations have been reported for AIB1 co-activator suppression (<xref ref-type="bibr" rid="B15">15</xref>), where AIB1 is necessary for E2-induced ERÎ± degradation, optimal binding of ERÎ± to target gene promoters and full ERÎ± transcriptional activity. Consequently, we investigated the effects of CK1Î´ silencing on AIB1 protein levels. MCF7 cells were transfected either with CT siRNA or CK1Î´ siRNA in the presence or absence of E2 (100ânM), followed by immunoblotting using a mouse monoclonal AIB1 antibody. Whereas in untreated, E2-treated and control siRNA-treated cells the AIB1 protein levels remained unaffected, treatment with CK1Î´ siRNA followed by E2 stimulation resulted in a 60% decrease of AIB1 protein levels (<xref ref-type="fig" rid="F4">Figure 4</xref>A and B). Moreover, overexpression of CK1Î´ in MCF7 cells resulted in stabilization of AIB1 (data not shown).
<fig id="F4" position="float"><label>Figure 4.</label><caption><p>CK1Î´ silencing decreases AIB1 protein levels in the presence of E2. (<bold>A</bold>) MCF7 cells (2âÃâ10<sup>5</sup>) were plated in 6-well plates in phenol red-free DMEM containing 10% DSS. Cells were untransfected or transfected with 5ânM CT siRNA or with 5ânM CK1Î´ siRNA for 72âh and treated or not with E2 (100ânM) for 45âmin. Cells were harvested, lysed and equal protein amounts were subjected to western blotting using a specific AIB1 mouse monoclonal antibody. Samples were probed for equal loading using a Î²-actin specific monoclonal antibody. (<bold>B</bold>) Quantitative analysis of AIB1 protein levels is given as fold of control. (<bold>C</bold>) MCF7 cells were untransfected or transfected with 5ânM CT siRNA or with 5ânM CK1Î´ siRNA for 72âh. Where indicated, cells were incubated with MG132 (5Î¼M) for 6âh and and then treated with E2 (100ânM) for 45âmin. Cell extracts were immunoblotted with AIB1 antibody. (<bold>D</bold>) Quantitative analysis of AIB1 protein levels with or without MG132 pre-treatment in the presence of E2. All data are representative results from two independent experiments. (<bold>E</bold>) Fluorescence microscopy was performed on either untransfected MCF7 cells or cells transfected with 5ânM CK1Î´ siRNA for 72âh followed by the addition of E2 (100ânM) for 45âmin. All cells were grown on coverslips, then fixed and stained as described in âMaterials and Methodsâ section.</p></caption><graphic xlink:href="gkp136f4"/></fig></p><p>Since AIB1 can be degraded through the 26S proteasome (as well as the REGÎ³-mediated proteasome pathway) we examined whether AIB1 downregulation could be rescued by MG132. Use of MG132 rescued the CK1Î´ siRNA-mediated decrease of AIB1 in E2-treated MCF7 cells (<xref ref-type="fig" rid="F4">Figure 4</xref>C and D) (similar results were obtained using another independent CK1Î´ siRNA). These results imply an involvement of CK1Î´ in the proteasome-dependent regulation of AIB1 expression.</p><p>The effects of CK1Î´ silencing on AIB1 protein levels were also investigated by IF, where MCF7 cells, untransfected or transfected with CK1Î´ siRNA, were stimulated with E2, and the subcellular localization of AIB1 was visualised using the AIB1 antibody. Treatment with CK1Î´ siRNA resulted in a significantly decrease in nuclear AIB1 compared to untreated cells, in the presence of E2 (<xref ref-type="fig" rid="F4">Figure 4</xref>E).</p></sec><sec><title>CK1Î´ associates with human ERÎ± and AIB1 and regulates their interactions</title><p>In order to clarify whether ERÎ± and AIB1 are physiological substrates for CK1Î´, we examined whether these proteins can physically associate <italic>in vivo</italic>. COS-1 cells were transiently transfected for 24âh with expression plasmids encoding for either: (i) ERÎ± and CK1Î´ or, (ii) AIB1 and CK1Î´, following treatment with or without 100ânM E2 for 30âmin. Subsequently, the potential interactions between: (i) ERÎ±âCK1Î´ and, (ii) AIB1-CK1Î´ were assessed by immunoprecipitation of CK1Î´ followed by analyses of the immune complexes for the presence of ERÎ± and AIB1 respectively. An association of CK1Î´ with ERÎ± as well as with AIB1 in the presence or absence of E2 was observed, although the interaction was reduced in the absence of E2 (<xref ref-type="fig" rid="F5">Figure 5</xref>A). In addition, CK1Î´ was able to co-precipitate with ERÎ± phosphorylated at S118, suggesting that it is able to interact with this form of ERÎ± (<xref ref-type="fig" rid="F5">Figure 5</xref>A).
<fig id="F5" position="float"><label>Figure 5.</label><caption><p>CK1Î´ associates with ERÎ± and AIB1 <italic>in vivo</italic> and regulates their interactions. (<bold>A</bold>) Lysates from untreated or E2-stimulated COS-1 cells were immunoprecipitated with CK1Î´ or non-immune IgG followed by immunoblotting with anti-ERÎ±, anti-pS118/ERÎ± and anti-AIB1. (<bold>B</bold>) MCF7 cells (i) untransfected or (ii) transfected with a (EYFP)-CK1Î´ plasmid were stimulated with 100ânM E2 for 30âmin before precipitation with anti-AIB1 antibody. The interaction between AIB1 and ERÎ± was visualised by western blotting using an anti-ERÎ± antibody. Equal amounts of protein were added in both lanes.</p></caption><graphic xlink:href="gkp136f5"/></fig></p><p>The ability of CK1Î´ to interact with the ERÎ±âAIB1 complex, led us to examine whether CK1Î´ is able to influence the interactions between ERÎ± and AIB1. To address this issue, we overexpressed CK1Î´ in MCF7 cells for 24âh, and performed co-immunoprecipitation experiments following treatment with 100ânM E2 for 30âmin. Our results showed that increased CK1Î´ protein levels resulted in an increased ERÎ±âAIB1 association, compared to untransfected cells, in the presence of E2 (<xref ref-type="fig" rid="F5">Figure 5</xref>B).</p><p>Overall, these data demonstrate that CK1Î´ is involved in the regulation of ERÎ±âAIB1 interactions, critical for the modulation of ERÎ± transcriptional activity.</p></sec><sec><title>CK1Î´ phosphorylates ERÎ± in the AF1-DBD domain and AIB1âat S601 <italic>in vitro</italic></title><p>Since the phosphorylation status of ERÎ± and AIB1 play essential roles in their functions, we examined the ability of CK1Î´ to phosphorylate these proteins. We performed <italic>in vitro</italic> kinase assays using the purified catalytic subunit of CK1 as source of enzyme activity. As ERÎ±-substrates we used: (i) full-length recombinant human ERÎ±, (ii) GST-recombinant human ERÎ± fragment encompassing the AF1 transactivation domain and the DNA-binding domain (aa 1â280) and (iii) GST-recombinant human ERÎ± fragment encompassing the LBD (aa 283â595) (<xref ref-type="fig" rid="F6">Figure 6</xref>A and B). As AIB1-substrates we used: (i) purified full-length AIB1 and (ii) GST-recombinant human AIB1 fragment encompassing the RID region, responsible for ligand-dependent interaction with NRs (aa 582â800) (<xref ref-type="fig" rid="F6">Figure 6</xref>C and D).
<fig id="F6" position="float"><label>Figure 6.</label><caption><p>CK1Î´ phosphorylates ERÎ± and AIB1 <italic>in vitro</italic>. (<bold>A</bold>) Schematic representation of human ERÎ±. AF: activator function. (<bold>B</bold>) <italic>In vitro</italic> kinase assays were performed using purified recombinant human CK1Î´ as source of enzyme and: (i) full-length recombinant human ERÎ±, (ii) GST-recombinant human ERÎ± (aa 1â280) and (iii) GST-recombinant human ERÎ± (aa 283â595), as substrates. (<bold>C</bold>) Schematic diagram of human AIB1 with its known functional domains. Î²HLS/PAS: basic helix-loop-helix/Per-Arnt-Sim domain; RID: receptor interacting domain; CID: CBP/p300 interacting domain; HAT: histone acetyltransferase domain. The positions of all identified phosphorylation amino acids are indicated. (<bold>D</bold>) <italic>In vitro</italic> kinase assays were performed using recombinant human CK1Î´ as source of enzyme and as substrates: (i) purified full-length AIB1 and (ii) GST-recombinant human AIB1 (aa 582â800). (<bold>E</bold>) CK1 phosphorylates one major residue of AIB1. GSTâAIB1 aa 582â800 was phosphorylated <italic>in vitro</italic> by the catalytic subunit of CK1 for the indicated times. Up to 1.6âmol phosphate/mol protein were incorporated into the GSTâAIB1 aa 582â800 fusion protein. (<bold>F</bold>) Phosphorylation of GSTâAIB1 fusion proteins by CK1Î´. <italic>In vitro</italic> kinase assays were performed using recombinant human CK1Î´ as the source of enzyme and: (i) GSTâAIB1 aa 582â800 (wt), (ii) GSTâAIB1 aa 582â800 (S664A), (iii) GSTâAIB1 aa 582â800 (T714A), (iv) GSTâAIB1 aa 582â800 (S715A), (v) GSTâAIB1 aa 582â800 (S794A) and (vi) GSTâAIB1 aa 582â800 (S601A), as substrates. Proteins were separated by SDS-PAGE and the phosphorylated proteins were detected by autoradiography. Quantification of phosphate incorporation of phosphorylated proteins was measured by Cerenkov counting. Error bars represent SD of two experiments, each in triplicate. C: Coomasie. A: Autoradiogram.</p></caption><graphic xlink:href="gkp136f6"/></fig></p><p>We demonstrated that CK1Î´ can phosphorylate ERÎ± <italic>in vitro</italic>, and its prospective phosphorylation target(s) are located within the AF1-DBD area of ERÎ± (<xref ref-type="fig" rid="F6">Figure 6</xref>B). Moreover, CK1Î´ was able to phosphorylate full-length AIB1 within aa 582â800 (<xref ref-type="fig" rid="F6">Figure 6</xref>D). Use of additional GST-fusion proteins containing fragments derived from AIB1 (containing aa 1â321, aa 321â581 and aa 841â1081) were not phosphorylated by CK1Î´ (our data not shown and also shown by others) (<xref ref-type="bibr" rid="B26">26</xref>).</p><p>Bioinformatic sequence examination (<ext-link ext-link-type="uri" xlink:href="http://scansite.mit.edu">http://scansite.mit.edu</ext-link>) revealed several potential CK1Î´ phosphorylation sites in the AF1-DBD domain of ERÎ± and in the region between aa 582 and 800 of AIB1.</p><p>In order to determine the stoichiometry of AIB1 phosphorylation by CK1Î´, we performed <italic>in vitro</italic> time course kinase assays using the GST-AIB1 fusion protein encompassing aa 582â800 as substrate and the purified catalytic subunit of CK1 as enzyme. Our results demonstrated that â¼1.6âmol of phosphate were incorporated per mol of protein, implying the existence of at least one major aa in AIB1 (within the region of aa 582â800) phosphorylated by CK1 <italic>in vitro</italic> (<xref ref-type="fig" rid="F6">Figure 6</xref>E). Subsequently, to identify the exact phosphorylation site(s) of AIB1, we generated different GST-AIB1 aa 582â800 fusion proteins baring mutations from S or T to A at various prospective aas (S601, S664, T714, S715, S794) that could be phosphorylated by CK1Î´. Our <italic>in vitro</italic> kinase assays clearly revealed that the AIB1 residues (i) S664, (ii) T714 and (iii) S715 were not targeted for phosphorylation by CK1 (<xref ref-type="fig" rid="F6">Figure 6</xref>F). Mutation of S794 to A resulted in a â¼10% reduction of phosphorylation compared to the wild-type GST-AIB1 aa 582â800, whilst the degree of phosphorylation of GST-AIB1 aa 582â800 S601A was less then 40% compared with that of wild type GST-AIB1 aa 582â800 (<xref ref-type="fig" rid="F6">Figure 6</xref>F). These results strongly suggest that the major site of AIB1 phosphorylated by CK1Î´ is S601.</p></sec><sec><title>Phosphorylation of S601 by CK1Î´ <italic>in vivo</italic> affects the co-activation function of AIB1</title><p>In order to examine the importance of S601 in relation to CK1Î´ phosphorylation <italic>in vivo</italic>, an AIB1 expression plasmid baring a mutation at S601A was generated (pCMV-Flag-AIB1/S601A). Following this, the effects of S601A mutant on the ability of AIB1 to function as a transcriptional co-activator was assessed by measuring the estrogen-dependent induction of endogenous pS2 mRNA levels in MCF7 cells, after increasing or decreasing CK1Î´ protein levels, respectively. In the presence of E2, transient co-transfections of wt AIB1 and CK1Î´ resulted in an increase (â¼60%) of pS2 gene expression levels, compared to untransfected cells (<xref ref-type="fig" rid="F7">Figure 7</xref>A), while a small increase (â¼10%) of pS2 mRNA levels was observed after over-expression of the AIB1/S601A mutant along with CK1Î´ (<xref ref-type="fig" rid="F7">Figure 7</xref>A). To further establish that the observed changes in the co-activation functions of AIB1 can be attributed to phosphorylation of S601 by CK1Î´, MCF7 cells were treated with 1Î¼M IC261 and pS2 mRNA levels were quantified. In accordance with âour hypothesisâ, in the presence of E2 inhibition of CK1Î´ led to decreased activity of wt AIB1 to basal pS2 mRNA levels (<xref ref-type="fig" rid="F7">Figure 7</xref>B) compared to over-expression of both wt AIB1 and CK1Î´. As expected, use of the IC261 inhibitor did not alter the activity of AIB1/S601A mutant (<xref ref-type="fig" rid="F7">Figure 7</xref>B). We conclude that these functional data indicate that phospho-S601 residue within the RID domain is necessary and sufficient for AIB1 co-activation functions.
<fig id="F7" position="float"><label>Figure 7.</label><caption><p>Functional role of CK1Î´-dependent phosphorylation of S601 in ERÎ±-dependent transcription. MCF7 cells (2âÃâ10<sup>5</sup>) were plated in 6-well plates in phenol red-free DMEM containing 10% DSS. (<bold>A</bold>) Cells were co-transfected either with 1Î¼g of: (i) pCMV-Flag-AIB1 and (EYFP)âCK1Î´ plasmids or, (ii) pCMV-Flag-AIB1/S601A and (EYFP)âCK1Î´ plasmids for 24âh. (<bold>B</bold>) Cells were transfected with 1Î¼g of: (i) pCMV-Flag-AIB1 and, (ii) pCMV-Flag-AIB1/S601A plasmid for 24âh, followed by treatment with 1âÎ¼M IC261 for 3âh. Subsequently, all cells were treated or not (vehicle) with E2 (10ânM) for 24âh. Cells were harvested and total RNA was extracted and used to synthesize cDNA by reverse transcription, as described in âMaterials and Methodsâ section. Gene expression of pS2 was measured by qRT-PCR. Error bars represent SD of two separate experiments, each in triplicate (<italic>P</italic>â&lt;â0.05).</p></caption><graphic xlink:href="gkp136f7"/></fig></p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Protein phosphorylation, an essential post-translational modification, regulates protein functions including activity, stability, subcellular localization and interactions with other proteins and substrates (<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>). Kinases are therefore considered key regulatory proteins and elucidation of their roles in signaling pathways is essential (<xref ref-type="bibr" rid="B35">35</xref>). In the present study, we have identified ERÎ± and AIB1 as novel substrates for CK1Î´ <italic>in vitro</italic> that are able to interact in a cellular context, proposing an involvement of CK1Î´ in regulating their interactions and functions. In addition, we have identified S601 within AIB1 as a novel phosphorylation site targeted by CK1Î´ <italic>in vitro</italic>, while AIB1-S601A mutant protein negatively influenced AIB1's co-activation function in ERÎ±-dependent transcription. Furthermore, using CK1Î´ siRNA in MCF7 breast cancer cells, we demonstrated that CK1Î´ is required for full ERÎ± transcriptional activity and is involved in the regulation of ERÎ± protein levels in the presence of E2. Finally, we have shown that suppression of CK1Î´ results in proteasome-mediated degradation of AIB1, in the presence of E2, implying that CK1Î´ phosphorylation protects AIB1 from proteolysis.</p><p>We examined the effects of CK1Î´ silencing on the transcriptional activity of ERÎ± and observed a 35% decrease in the E2 response of an integrated ERE reporter gene. Moreover, the effects of CK1Î´ silencing on the expression levels of two endogenous estrogen-responsive genes, pS2 and PR, resulted in reductions of 55% and 43% respectively when CK1Î´ siRNA was used, while the reductions were even higher (69% and 66%) in the presence of a CK1Î´ inhibitor (IC261). In contrast, overexpression of CK1Î´ resulted in a 2-fold increase in pS2 mRNA levels. <italic>In vitro</italic> kinase assays using the CK1Î´ as enzyme and different ERÎ± fragments as substrates showed that CK1Î´ predominantly phosphorylates the AF1 domain of ERÎ±. Thus far, various kinases have been identified that can phosphorylate the AF1 domain and thereby regulate ERÎ± activity (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B36">36</xref>). In this report, we identify a novel involvement of CK1 as a direct and/or indirect regulator of ERÎ± transcriptional activity.</p><p>Since phosphorylation of ERÎ± S118 is correlated with ERÎ± activity, we next examined phospho-S118 levels in MCF7 cells following CK1Î´ silencing. Our results demonstrate increased phospho-S118 levels that paradoxically followed a CK1Î´ siRNA-induced dependent increase in total ERÎ±. These data suggest that S118 is not phosphorylated by CK1Î´ implicating other unidentified ERÎ± site(s) as targets for CK1Î´, which eventually could modulate the activity of ERÎ±. However, CK1Î´ appears to be involved in the regulation of ERÎ± protein levels, as demonstrated in two different breast cancer cell lines (MCF7 and T47D) after treatment with CK1Î´ siRNA resulting in ERÎ± stabilization. It is well known that ERÎ± protein turnover occurs through the proteasome in a cyclic manner, dependent on ligand binding, which ensures a stable and balanced cellular level of the receptor (<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B37">37</xref>). Moreover, it has been reported that the differential transcriptional activity of ERÎ± produced upon binding of different synthetic ligands (SERMs), correlates with the degradation rate of ERÎ± (<xref ref-type="bibr" rid="B38">38</xref>), with higher activities corresponding to faster degradation. Various kinases and multiple agents that activate or inhibit phosphorylation have been implicated in modifying the proteasome-mediated stability of ERÎ± and consequently its activity (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B39 B40 B41">39â41</xref>). Taken together, our data suggest that CK1 represents a new protein kinase involved in the stabilization of ERÎ±.</p><p>Additionally, several observations have linked the recruitment of ERÎ± co-factors with ligand-dependent degradation of ERÎ±. Particularly in the case of AIB1, it has been shown that siRNA-mediated silencing of AIB1 results in ERÎ± stabilization, but a loss in ERÎ± activity. This stabilization correlates with a reduction in recruitment of components of the ubiquitin proteasome machinery (<xref ref-type="bibr" rid="B15">15</xref>). Therefore, we have also examined the effects of CK1Î´ silencing on AIB1 protein levels. CK1Î´ siRNA treatment in the presence of E2 produced a 60% decrease in AIB1 protein levels, an effect that was confirmed by IF, where the overall fluorescent signal of AIB1 was markedly weaker when cells were treated with CK1Î´ siRNA. The decrease in AIB1 levels was rescued by proteasome inhibition, implicating CK1Î´ in the regulation of AIB1 proteasome-mediated degradation.</p><p>Our <italic>in vitro</italic> kinase assays demonstrated that AIB1, in addition to ERÎ±, can be a substrate for CK1Î´ phosphorylation. Use of an AIB1 GST-fusion protein revealed that the prospective phosphorylation site(s) of AIB1 targeted by CK1Î´ are located within amino acids 582â800, which encompass the RID domain of AIB1, required for interactions with NRs. Time-course experiments revealed that there is one major phosphorylation site for CK1 within aa 582â800 of AIB1. <italic>In vitro</italic> kinase assays using various GSTâAIB1 fusion proteins as substrates revealed that CK1 mainly phosphorylates S601 in AIB1, a hitherto unidentified phosphosite. The presence of a serine residue at position <italic>n</italic>âââ3 of S601 (K<sup>596</sup>E<bold>S</bold>KES<sup>601</sup>) resembles the optimal consensus recognition motif for CK1 (<xref ref-type="bibr" rid="B42">42</xref>), thereby favouring S601 as the main phosphorylation site targeted by CK1. Examination of the role of S601 revealed a physiological importance of this site in the activity of AIB1 in breast cancer cells, after demonstrating that mutation of this aa negatively influenced the expression levels of the E2-dependent pS2 genes. However, additional experiments are required in order to elucidate the exact molecular mechanism of the involvement of S601 in the regulation of AIB1's co-activation function.</p><p>Our data herein, reveal an association of CK1Î´ with ERÎ± and AIB1, which can result in a complex formation that enables CK1Î´ to interact, phosphorylate and exert its effects by regulating the interaction between ERÎ± and AIB1 and thereby modulate the functions of these two proteins.</p><p>AIB1 is a target for multiple signaling pathways and its phosphorylation state is a determinant of its functionality including degradation and interactions with other proteins (<xref ref-type="bibr" rid="B17">17</xref>). Phosphorylation of AIB1 by different kinases has been associated with increased AIB1 degradation (<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>); however, a recent report (<xref ref-type="bibr" rid="B10">10</xref>) identified aPKC as the first kinase able to stabilize AIB1 in cancer cells and thereby enhance its activity. Based on our results, we propose a model where CK1Î´ protects AIB1 from proteolysis, as part of a balanced equilibrium in which kinases are required to maintain a consistent protein level of AIB1 (<xref ref-type="fig" rid="F8">Figure 8</xref>). However, aberrations in this balance towards CK1Î´, as occurs in breast cancer, would be expected to increase AIB1 levels, and therefore also the expression of ERÎ±-respondent target genes. These genes are critical to breast cancer growth, as evidenced by the successes in the use of anti-estrogens to treat breast cancer, so we speculate here that increases in their expression may be a determinant of cancer progression and/or resistance to anti-estrogens. It is interesting to note here that both the receptor and its co-activator partner are subject to phosphorylation by the same kinase, introducing hierarchical, sequential or simultaneous phosphorylation possibilities in this dual regulatory pathway. However, using purified substrates in the <italic>in vitro</italic> kinase assays suggests that CK1Î´ can interact with and phosphorylate both independently.
<fig id="F8" position="float"><label>Figure 8.</label><caption><p>A model for the regulation of ERÎ± transcriptional activity, involving CK1Î´ and AIB1. In the presence of E2, CK1Î´ interacts with and phosphorylates AIB1 predominantly at S601 and probably ERÎ± at other site(s), inducing the formation of a complex between them that is required for the complete transcriptional activity of ERÎ±. Inhibition of CK1Î´-mediated phosphorylation, potentially alters the conformation of AIB1 and promotes its proteasome-mediated degradation; subsequently, ERÎ± protein levels are stabilized and ERÎ± activity is decreased.</p></caption><graphic xlink:href="gkp136f8"/></fig></p><p>Our results, identifying a novel AIB1 phosphorylation site (S601) that affects the co-activation function of AIB1, in conjunction with a new report which suggests that tyrosine phosphorylation of AIB1 is also required for its activity (<xref ref-type="bibr" rid="B43">43</xref>) demonstrate the importance of post-translational modifications as an additional level of transcriptional regulation. Generation of a phospho-specific antibody against S601 in AIB1 is currently underway; correlations between phosphorylated levels of AIB1âat S601 in breast cancer samples and clinical outcome parameters such as time to progression, overall survival and clinical endocrine resistance, remain to be tested.</p><p>It has already been shown that ERÎ± and AIB1 shuttle between the cytoplasm and the nucleus (<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>). Phosphorylation events induced by different kinases occur in both compartments influencing their functions, including stability, mobility and activity (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B46 B47 B48 B49">46â49</xref>) as per our proposed model (<xref ref-type="fig" rid="F8">Figure 8</xref>). In this report we identify CK1Î´, a predominantly cytoplasmic protein (<xref ref-type="bibr" rid="B50">50</xref>,<xref ref-type="bibr" rid="B51">51</xref>), as a novel kinase implicated in the modulation of physiological aspects of both ERÎ± and AIB1.</p></sec><sec><title>SUPPLEMENTARY DATA</title><p><ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp136/DC1">Supplementary Data</ext-link> are available at NAR Online.</p></sec><sec><title>FUNDING</title><p>Citrina Foundation, the family of Janet Booker and the Hammersmith Hospitalsâ Trusteesâ Research Committee.</p><p><italic>Conflict of interest statement</italic>. None declared.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>[Supplementary Data]</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="gkp136_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="gkp136_nar-00099-x-2009-File010.doc"/>
<media xlink:role="associated-file" mimetype="image" mime-subtype="jpeg" xlink:href="gkp136_nar-00099-x-2009-File011.jpg"/>
</supplementary-material>
</sec>
</body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p>We are indebted to Professors Bert W. OâMalley and Simak Ali for their advice and critical reviews of this work. We would also like to thank Dr Elena Kulinskaya of the Statistical Advisory Service (Imperial College, London) for helping with the statistical analyses of our data.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cordera</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jordan</surname>
              <given-names>VC</given-names>
            </name>
          </person-group>
          <article-title>Steroid receptors and their role in the biology and control of breast cancer growth</article-title>
          <source>Semin. Oncol.</source>
          <year>2006</year>
          <volume>33</volume>
          <fpage>631</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">17145341</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ali</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Coombes</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Endocrine-responsive breast cancer and strategies for combating resistance</article-title>
          <source>Nat. Rev. Cancer</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>101</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">12635173</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lannigan</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Estrogen receptor phosphorylation</article-title>
          <source>Steroids</source>
          <year>2003</year>
          <volume>68</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">12475718</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alarid</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Bakopoulos</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Solodin</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation</article-title>
          <source>Mol. Endocrinol.</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>1522</fpage>
          <lpage>1534</lpage>
          <pub-id pub-id-type="pmid">10478843</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lonard</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Nawaz</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation</article-title>
          <source>Mol. Cell</source>
          <year>2000</year>
          <volume>5</volume>
          <fpage>939</fpage>
          <lpage>948</lpage>
          <pub-id pub-id-type="pmid">10911988</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nawaz</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lonard</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Dennis</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>Proteasome-dependent degradation of the human estrogen receptor</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>1858</fpage>
          <lpage>1862</lpage>
          <pub-id pub-id-type="pmid">10051559</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Preisler-Mashek</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Solodin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Tyriver</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Alarid</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
          <article-title>Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha</article-title>
          <source>Am. J. Physiol. Endocrinol. Metab.</source>
          <year>2002</year>
          <volume>282</volume>
          <fpage>E891</fpage>
          <lpage>898</lpage>
          <pub-id pub-id-type="pmid">11882509</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grisouard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Medunjanin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hermani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shukla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor</article-title>
          <source>Mol. Endocrinol.</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>2427</fpage>
          <lpage>2439</lpage>
          <pub-id pub-id-type="pmid">17609434</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valley</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Metivier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Solodin</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Fowler</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Mashek</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alarid</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
          <article-title>Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>5417</fpage>
          <lpage>5428</lpage>
          <pub-id pub-id-type="pmid">15964799</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Amazit</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lonard</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>OâMalley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1</article-title>
          <source>Mol. Cell</source>
          <year>2008</year>
          <volume>29</volume>
          <fpage>465</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="pmid">18313384</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anzick</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Kononen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Azorsa</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Guan</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Sauter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Meltzer</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>277</volume>
          <fpage>965</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="pmid">9252329</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Wrange</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The role of chromatin in transcriptional regulation</article-title>
          <source>Int. J. Biochem. Cell Biol.</source>
          <year>1997</year>
          <volume>29</volume>
          <fpage>731</fpage>
          <lpage>742</lpage>
          <pub-id pub-id-type="pmid">9251241</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suen</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Berrodin</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Mastroeni</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cheskis</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Lyttle</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Frail</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity</article-title>
          <source>J. Biol. Chem.</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>27645</fpage>
          <lpage>27653</lpage>
          <pub-id pub-id-type="pmid">9765300</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torchia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Inostroza</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kamei</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Westin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Glass</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function</article-title>
          <source>Nature</source>
          <year>1997</year>
          <volume>387</volume>
          <fpage>677</fpage>
          <lpage>684</lpage>
          <pub-id pub-id-type="pmid">9192892</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Keeton</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>McDonnell</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Coactivator AIB1 links estrogen receptor transcriptional activity and stability</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>11599</fpage>
          <lpage>11604</lpage>
          <pub-id pub-id-type="pmid">15289619</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gianni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parrella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Raska</surname>
              <given-names>I</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Gaillard</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nigro</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Gaudon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Garattini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rochette-Egly</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcription</article-title>
          <source>EMBO J.</source>
          <year>2006</year>
          <volume>25</volume>
          <fpage>739</fpage>
          <lpage>751</lpage>
          <pub-id pub-id-type="pmid">16456540</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Lonard</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>OâMalley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock</article-title>
          <source>Cell</source>
          <year>2007</year>
          <volume>129</volume>
          <fpage>1125</fpage>
          <lpage>1140</lpage>
          <pub-id pub-id-type="pmid">17574025</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gross</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family</article-title>
          <source>Cell Signal.</source>
          <year>1998</year>
          <volume>10</volume>
          <fpage>699</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="pmid">9884021</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knippschild</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Gocht</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lohler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stoter</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The casein kinase 1 family: participation in multiple cellular processes in eukaryotes</article-title>
          <source>Cell Signal.</source>
          <year>2005</year>
          <volume>17</volume>
          <fpage>675</fpage>
          <lpage>689</lpage>
          <pub-id pub-id-type="pmid">15722192</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuja</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Osann</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Bryant</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Somatic mutations and altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal carcinoma</article-title>
          <source>Cancer Res.</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>942</fpage>
          <lpage>951</lpage>
          <pub-id pub-id-type="pmid">14871824</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von Blume</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Knippschild</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Dequiedt</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giamas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Auer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Lint</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Adler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Seufferlein</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2</article-title>
          <source>EMBO J.</source>
          <year>2007</year>
          <volume>26</volume>
          <fpage>4619</fpage>
          <lpage>4633</lpage>
          <pub-id pub-id-type="pmid">17962809</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brockschmidt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hirner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Eismann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hillenbrand</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giamas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Radunsky</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ammerpohl</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Henne-Bruns</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo</article-title>
          <source>Gut</source>
          <year>2008</year>
          <volume>57</volume>
          <fpage>799</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="pmid">18203806</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giamas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hirner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shoshiashvili</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Grothey</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gessert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kuhl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Henne-Bruns</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vorgias</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Knippschild</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylation of CK1delta: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo</article-title>
          <source>Biochem. J.</source>
          <year>2007</year>
          <volume>406</volume>
          <fpage>389</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="pmid">17594292</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bamberger</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Aslan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kurth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Speidel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Loning</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lohler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Henne-Bruns</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells</article-title>
          <source>Oncogene</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>7964</fpage>
          <lpage>7975</lpage>
          <pub-id pub-id-type="pmid">16027726</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Woolf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Neklason</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Branford</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Yost</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Burt</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Virshup</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism</article-title>
          <source>Int. J. Cancer</source>
          <year>2007</year>
          <volume>120</volume>
          <fpage>1005</fpage>
          <lpage>1012</lpage>
          <pub-id pub-id-type="pmid">17131344</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways</article-title>
          <source>Mol. Cell</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>937</fpage>
          <lpage>949</lpage>
          <pub-id pub-id-type="pmid">15383283</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tora</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tasset</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Scheer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chambon</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The human estrogen receptor has two independent nonacidic transcriptional activation functions</article-title>
          <source>Cell</source>
          <year>1989</year>
          <volume>59</volume>
          <fpage>477</fpage>
          <lpage>487</lpage>
          <pub-id pub-id-type="pmid">2805068</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balaguer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Francois</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Comunale</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fenet</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Boussioux</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Pons</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nicolas</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Casellas</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Reporter cell lines to study the estrogenic effects of xenoestrogens</article-title>
          <source>Sci. Total Environ.</source>
          <year>1999</year>
          <volume>233</volume>
          <fpage>47</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">10492897</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen</article-title>
          <source>Endocrinology</source>
          <year>2007</year>
          <volume>148</volume>
          <fpage>4634</fpage>
          <lpage>4641</lpage>
          <pub-id pub-id-type="pmid">17615152</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behrend</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Milne</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Stoter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Deppert</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Meek</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Knippschild</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>5303</fpage>
          <lpage>5313</lpage>
          <pub-id pub-id-type="pmid">11103931</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Riedl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Washbrook</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pace</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Coombes</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Egly</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7</article-title>
          <source>Mol. Cell</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>127</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="pmid">10949034</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Washbrook</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sarwar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Pace</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Thirunuvakkarasu</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Fuller-Pace</surname>
              <given-names>FV</given-names>
            </name>
            <name>
              <surname>Egly</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera</article-title>
          <source>Oncogene</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>4921</fpage>
          <lpage>4931</lpage>
          <pub-id pub-id-type="pmid">12118371</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kennelly</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Archaeal protein kinases and protein phosphatases: insights from genomics and biochemistry</article-title>
          <source>Biochem. J.</source>
          <year>2003</year>
          <volume>370</volume>
          <fpage>373</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="pmid">12444920</pub-id>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kostich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Madison</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gheyas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Laz</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Human members of the eukaryotic protein kinase family</article-title>
          <source>Genome Biol.</source>
          <year>2002</year>
          <volume>3</volume>
          <comment>RESEARCH0043</comment>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giamas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stebbing</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vorgias</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Knippschild</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Protein kinases as targets for cancer treatment</article-title>
          <source>Pharmacogenomics</source>
          <year>2007</year>
          <volume>8</volume>
          <fpage>1005</fpage>
          <lpage>1016</lpage>
          <pub-id pub-id-type="pmid">17716234</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Medunjanin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hermani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Servi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Grisouard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rincke</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity</article-title>
          <source>J. Biol. Chem.</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>33006</fpage>
          <lpage>33014</lpage>
          <pub-id pub-id-type="pmid">16076840</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reid</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hubner</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Metivier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Brand</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Denger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Manu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Beaudouin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ellenberg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gannon</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling</article-title>
          <source>Mol. Cell</source>
          <year>2003</year>
          <volume>11</volume>
          <fpage>695</fpage>
          <lpage>707</lpage>
          <pub-id pub-id-type="pmid">12667452</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wijayaratne</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>McDonnell</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators</article-title>
          <source>J. Biol. Chem.</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>35684</fpage>
          <lpage>35692</lpage>
          <pub-id pub-id-type="pmid">11473106</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Callige</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kieffer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Richard-Foy</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>4349</fpage>
          <lpage>4358</lpage>
          <pub-id pub-id-type="pmid">15899841</pub-id>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henrich</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kitt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Errington</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Traish</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lannigan</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>5979</fpage>
          <lpage>5988</lpage>
          <pub-id pub-id-type="pmid">12917323</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marsaud</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gougelet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maillard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Renoir</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells</article-title>
          <source>Mol. Endocrinol.</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>2013</fpage>
          <lpage>2027</lpage>
          <pub-id pub-id-type="pmid">12855746</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flotow</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Graves</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>AQ</given-names>
            </name>
            <name>
              <surname>Fiol</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Roeske</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Roach</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Phosphate groups as substrate determinants for casein kinase I action</article-title>
          <source>J. Biol. Chem.</source>
          <year>1990</year>
          <volume>265</volume>
          <fpage>14264</fpage>
          <lpage>14269</lpage>
          <pub-id pub-id-type="pmid">2117608</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Lahusen</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Chien</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Fereshteh</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Dakshanamurthy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kagan</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Wellstein</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Riegel</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2008</year>
          <volume>28</volume>
          <fpage>6580</fpage>
          <lpage>6593</lpage>
          <pub-id pub-id-type="pmid">18765637</pub-id>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amazit</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pasini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Szafran</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Berno</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Mielke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Mancini</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Hinojos</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>OâMalley</surname>
              <given-names>BW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>6913</fpage>
          <lpage>6932</lpage>
          <pub-id pub-id-type="pmid">17646391</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dauvois</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling</article-title>
          <source>J. Cell Sci.</source>
          <year>1993</year>
          <volume>106</volume>
          <issue>Pt 4</issue>
          <fpage>1377</fpage>
          <lpage>1388</lpage>
          <pub-id pub-id-type="pmid">8126115</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2002</year>
          <volume>22</volume>
          <fpage>5835</fpage>
          <lpage>5845</lpage>
          <pub-id pub-id-type="pmid">12138194</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gaynor</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation</article-title>
          <source>Mol. Cell</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>71</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">15808510</pub-id>
        </element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional regulation by steroid receptor coactivator phosphorylation</article-title>
          <source>Endocr. Rev.</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>393</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="pmid">15814849</pub-id>
        </element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>BW</given-names>
            </name>
          </person-group>
          <article-title>Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor</article-title>
          <source>Mol. Cell Biol.</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>8273</fpage>
          <lpage>8284</lpage>
          <pub-id pub-id-type="pmid">16135815</pub-id>
        </element-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behrend</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stoter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kurth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rutter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Heukeshoven</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Deppert</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Knippschild</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Interaction of casein kinase 1 delta (CK1delta) with post-Golgi structures, microtubules and the spindle apparatus</article-title>
          <source>Eur. J. Cell Biol.</source>
          <year>2000</year>
          <volume>79</volume>
          <fpage>240</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="pmid">10826492</pub-id>
        </element-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milne</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Looby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Meek</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Catalytic activity of protein kinase CK1 delta (casein kinase 1delta) is essential for its normal subcellular localization</article-title>
          <source>Exp. Cell Res.</source>
          <year>2001</year>
          <volume>263</volume>
          <fpage>43</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">11161704</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>